Systemic therapy options for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial studies which systemic treatments (medicines that travel through the blood to reach cancer cells) work best for patients with advanced liver cancer. It aims to find the most effective approach to slow tumor growth and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (hepatocellular carcinoma).
- Your liver function is good to moderate (Child-Pugh class A or B7, meaning your liver is still working fairly well).
- You are physically active and able to care for yourself (ECOG performance status 0 or 1).
- Your cancer is at an advanced stage (BCLC stage C) or is a large, widespread tumor (BCLC stage B with specific features) or has progressed after a procedure called TACE (chemoembolization).
- You have not received other treatments that are considered the standard first option for your condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
This trial tests whether adding systemic therapy (anticancer drugs) to surgery helps people with liver cancer that has spread to other parts of the body. It aims to improve outcomes by treating both the liver tumor and the metastases.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.